On Tuesday shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) closed at $59.50. On April 23, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), announced that it has received two orphan drug designations for triheptanoin (UX007). The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted orphan drug designation for triheptanoin for the treatment of fatty acid oxidation disorders (FAOD), and the European Commission has granted orphan medicinal product designation for the treatment of glucose transporter type-1 deficiency syndrome (Glut1 DS). The FDA granted orphan drug designation for triheptanoin in Glut1 DS in October 2014.
On last trading day Centene Corp. (NYSE:CNC) fell -2.47% to close at $69.04. Its volatility for the week is 4.01% while volatility for the month is 2.41%. CNC’s sales growth for past 5 years was 32.20% and its EPS growth for past 5 years was 18.10%. Centene Corp. (NYSE:CNC) monthly performance is -0.26%. Centene Corp. (NYSE:CNC) announced Monday that it has named a new chief medical officer. Dr. Ken Yamaguchi has been named to the position effective immediately. His official title will be executive vice president and CMO.
On Tuesday shares of Owens-Illinois, Inc. (NYSE:OI) closed at $25.14. Company’s sales growth for last 5 years was 0.40% and EPS growth for next 5 years is recorded as 5.62%. Owens-Illinois, Inc. (NYSE:OI), reported net income for the first quarter of $71 million or $0.44 per share, compared to $101 million or $0.61 per share for the year-ago quarter.
Edison International (NYSE:EIX) in last trading activity moved up 1.07% to close at $61.66. Company weekly performance is 1.92% while its quarterly performance stands at -9.21%. Edison International (NYSE:EIX) is -10.80% away from its 52 week high. Edison International (NYSE:EIX) on Tuesday reported first-quarter net income of $318 million. The Rosemead, California-based company said it had net income of 91 cents per share. Earnings, adjusted for non-recurring gains, came to 89 cents per share.
On last trading day Vectren Corporation (NYSE:VVC) advanced 0.82% to close at $44.30. Its volatility for the week is 2.17% while volatility for the month is 1.73%. VVC’s sales growth for past 5 years was 4.60% and its EPS growth for past 5 years was 4.30%. Vectren Corporation (NYSE:VVC) monthly performance is 1.23%. Vectren Corporation (NYSE:VVC) will announce its 2015 first quarter results after the market closes on Wednesday, May 6, 2015. Vectren management will discuss those results during a conference call at 2:00 p.m. EDT on Thursday, May 7, 2015.